Martin J. Driscoll Buys 5,000 Shares of Spring Bank Pharmaceuticals Inc (SBPH) Stock

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) insider Martin J. Driscoll bought 5,000 shares of the stock in a transaction dated Tuesday, May 21st. The shares were acquired at an average price of $6.63 per share, for a total transaction of $33,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of NASDAQ:SBPH traded down $0.20 during midday trading on Friday, hitting $6.53. 24,348 shares of the stock were exchanged, compared to its average volume of 32,825. The company has a market capitalization of $107.37 million, a PE ratio of -3.49 and a beta of 0.53. The company has a quick ratio of 12.11, a current ratio of 12.11 and a debt-to-equity ratio of 0.06. Spring Bank Pharmaceuticals Inc has a twelve month low of $6.30 and a twelve month high of $15.00.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last announced its earnings results on Monday, April 29th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.20. As a group, equities analysts anticipate that Spring Bank Pharmaceuticals Inc will post -2.26 earnings per share for the current year.

A number of brokerages have recently issued reports on SBPH. Zacks Investment Research lowered shares of Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 15th. Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research report on Monday, May 13th. Chardan Capital set a $25.00 price objective on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, April 12th. Cantor Fitzgerald set a $29.00 price objective on shares of Spring Bank Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, April 12th. Finally, ValuEngine lowered shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $23.80.

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Spring Bank Pharmaceuticals by 34.8% in the 3rd quarter. Vanguard Group Inc. now owns 549,186 shares of the company’s stock valued at $6,618,000 after purchasing an additional 141,730 shares in the last quarter. BlackRock Inc. raised its position in shares of Spring Bank Pharmaceuticals by 11.8% during the 4th quarter. BlackRock Inc. now owns 675,333 shares of the company’s stock valued at $7,017,000 after acquiring an additional 71,266 shares in the last quarter. Vanguard Group Inc raised its position in shares of Spring Bank Pharmaceuticals by 34.8% during the 3rd quarter. Vanguard Group Inc now owns 549,186 shares of the company’s stock valued at $6,618,000 after acquiring an additional 141,730 shares in the last quarter. Fosun International Ltd acquired a new stake in shares of Spring Bank Pharmaceuticals during the 4th quarter valued at approximately $274,000. Finally, Hikari Power Ltd raised its position in shares of Spring Bank Pharmaceuticals by 372.3% during the 4th quarter. Hikari Power Ltd now owns 53,536 shares of the company’s stock valued at $556,000 after acquiring an additional 42,200 shares in the last quarter. 43.03% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Martin J. Driscoll Buys 5,000 Shares of Spring Bank Pharmaceuticals Inc (SBPH) Stock” was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thestockobserver.com/2019/05/25/martin-j-driscoll-buys-5000-shares-of-spring-bank-pharmaceuticals-inc-sbph-stock.html.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).

Further Reading: LIBOR

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.